Page last updated: 2024-08-17

trifluridine and olaparib

trifluridine has been researched along with olaparib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Alruwaili, MM; Bakin, AV; Eng, KH; Fountzilas, C; Iyer, R; Melendy, T; Melnick, M; Park, BH; Smith, B; Wang, M; Zonneville, J	1

Other Studies

2 other study(ies) available for trifluridine and olaparib

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Communications biology, 2021, 07-12, Volume: 4, Issue:1 Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA Repair; Drug Combinations; Female; Humans; Mice, Inbred BALB C; Mice, SCID; Mutation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrrolidines; Signal Transduction; Thymine; Trifluridine; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2021

Article

Year

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.

Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.

Communications biology, 2021, 07-12, Volume: 4, Issue:1

Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA Repair; Drug Combinations; Female; Humans; Mice, Inbred BALB C; Mice, SCID; Mutation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrrolidines; Signal Transduction; Thymine; Trifluridine; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2021